EUVIMEDEUVIMED entdecken
Crossref

P-21: Real-world clinical experience with immunomodulating therapy in pediatric patients with stage 2 type 1 diabetes

M Ferrer-Lozano, N Itza Martín, B Rodán Martín, M Vara Callau, M P Ranchal Pérez, A M Peinado Garrido, I García de Pablo, C Ontoria Betancort

Hormone Research in Paediatrics · 04.11.2026 · 99 (Supplement_4)

DOI: 10.1159/hrp/adaag020.082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hormone Research in Paediatrics, online erschienen am 04.11.2026. Verfasst von M Ferrer-Lozano und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Identifying presymptomatic T1D enables immunomodulatory interventions to delay progression to Stage 3. Teplizumab, an anti-CD3 monoclonal antibody, has been shown to delay the onset of clinical T1D in Stage 2 patients. Real-world clinical experience remains limited.

Objectives

To describe baseline characteristics, treatment tolerance, and early safety profile of pediatric patients with Stage 2 T1D treated with teplizumab in Spain.

Methods

Observational, descriptive study based on a multicenter registry of pediatric diabetes units in Spain. Stage 2 T1D patients who received teplizumab were included. Demographics, family history, autoantibodies, laboratory parameters and CGM metrics were collected. Adverse events during the infusion period were recorded. Descriptive Statistical analysis were perrformed.

Results

Nine patients with Stage 2 T1D treated with teplizumab were included. Median age 13 years, 66.7% female. Five patients (55.5%) had a first-degree relative T1D. Associated autoimmune diseases were present in 22%. GADA and IA2A were detected in 100% of patients, IAA in 22%. Baseline median HbA1C 5.9%, glucose 92 mg/dL, C-peptide 1.1 ng/ml. Baseline CGM showed TITR 85%, time >140 mg/dL 12%, mean glucose 111 mg/dL and CV 21%. All patients completed full 14-day teplizumab cycle. A midline venous access was used in 55%. Most frequent AEs were: lymphopenia (100%), with <500 cells/µL in 55% of cases peaking on the fifth infusion day (78%); leukopenia (66%); skin rash (55%); asthenia (44%), nausea/vomiting (44%) and transient elevation of transaminases (11%). There were no serious adverse events and all AEs resolved within 7 days after the end of infusion.

Conclusions

This initial multicenter real-world experience in pediatric population suggests the use of teplizumab in patients with Stage 2 T1D has a favorable safety profile. Ongoing follow-up will assess impact of treatment on progression to clinical diabetes, and the added value of CGM in risk stratification during presymptomatic phases of the disease.

Zitieren

APA

Ferrer-Lozano, M., Martín, N. I., Martín, B. R., Callau, M. V., Pérez, M. P. R., Garrido, A. M. P., Pablo, I. G. D., & Betancort, C. O. (2026). P-21: Real-world clinical experience with immunomodulating therapy in pediatric patients with stage 2 type 1 diabetes. Hormone Research in Paediatrics, 99(Supplement_4). https://doi.org/10.1159/hrp/adaag020.082

Vancouver

Ferrer-Lozano M, Martín NI, Martín BR, Callau MV, Pérez MPR, Garrido AMP, et al. P-21: Real-world clinical experience with immunomodulating therapy in pediatric patients with stage 2 type 1 diabetes. Hormone Research in Paediatrics. 2026;99(Supplement_4). doi:10.1159/hrp/adaag020.082

BibTeX
@article{FerrerLozano2026,
  author = {Ferrer-Lozano, M and Martín, N Itza and Martín, B Rodán and Callau, M Vara and Pérez, M P Ranchal and Garrido, A M Peinado and Pablo, I García de and Betancort, C Ontoria},
  title = {P-21: Real-world clinical experience with immunomodulating therapy in pediatric patients with stage 2 type 1 diabetes},
  journal = {Hormone Research in Paediatrics},
  year = {2026},
  volume = {99},
  number = {Supplement_4},
  doi = {10.1159/hrp/adaag020.082}
}
Kostenlos starten →